3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Dermatologic
1
Conditions
Melanoma
12
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
5
Leukemia, Myeloid, Chronic-Phase
3
Polycythemia Vera
2
Neoplasm Metastasis
2
Carcinoma, Renal Cell
2
Uveal Melanoma
1
Unspecified Adult Solid Tumor, Protocol Specific
1
Thrombocythemia, Essential
1
Squamous Cell Carcinoma of Head and Neck
1
Skin Neoplasms
1
Recurrence
1
Primary Myelofibrosis
1
Osteosarcoma
1
Neurofibromatosis 1
1
Neurofibroma, Plexiform
1
Neurofibroma
1
Neoplasms
1
Metastatic Gastrointestinal Carcinoid Tumor
1
Lymphoma, Non-Hodgkin
1
Leukemia-Lymphoma, Adult T-Cell
1
Leukemia
1
Kidney Neoplasms
1
Hematologic Neoplasms
1
Head and Neck Neoplasms
1
Graft vs Host Disease
1
Glioma
1
Drug-Related Side Effects and Adverse Reactions
1
Carcinoma, Squamous Cell
1
Carcinoma, Hepatocellular
1
Interventions
Amifostine
12
Cisplatin
10
Radiotherapy
8
Etoposide
8
Cyclophosphamide
5
Paclitaxel
4
Filgrastim
4
Gemcitabine
3
Cytarabine
3
Carboplatin
3
denileukin diftitox
2
apatinib
2
Vincristine
2
Pyridoxine
2
Irinotecan
2
Ifosfamide
2
Fibroblast Growth Factor 7
2
Epoetin Alfa
2
Doxorubicin
2
Dexamethasone
2
Chemotherapy, Adjuvant
2
Bleomycin
2
uridine triacetate
1
sargramostim
1
peginterferon alfa-2b
1
pegfilgrastim
1
pegaspargase
1
eribulin
1
camrelizumab
1
Vitamin E
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Drug-Related Side Effects and Adverse Reactions
×
peginterferon alfa-2b
×
Clear all
NCT00221702
2010-10-13
EADO
University Hospital, Bordeaux
Phase 3
Completed
898 enrolled